|drug1637||Impact of Event Scale-Revised Wiki||1.00|
|drug3655||Wearing surgical face mask sprayed with hypertonic saline Wiki||1.00|
|drug1015||Depression, Anxiety and Stress Scale Wiki||1.00|
|D000066553||Problem Behavior NIH||0.33|
|D001523||Mental Disorders NIH||0.22|
There is one clinical trial.
Given the possible risks and complications of a comorbidity between psychiatric disorder and coronavirus disease 2019 (COVID-19), it seems particularly important to specify the impact of the COVID-19 pandemic in patients with psychiatric disorders and suspected of infection, hospitalized in a specific unit, at the psychiatric, somatic and pharmacological level.
Description: total severity score from the Impact of Event Scale-Revised (IES-R)Measure: impact of the COVID-19 pandemic on psychiatric symptomatology Time: through study completion, an average of 2 year
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports